nodes	percent_of_prediction	percent_of_DWPC	metapath
Imipramine—CYP1A2—Riluzole—amyotrophic lateral sclerosis	0.162	1	CbGbCtD
Imipramine—Alveolitis allergic—Riluzole—amyotrophic lateral sclerosis	0.0238	0.0579	CcSEcCtD
Imipramine—HTR2A—phrenic nerve—amyotrophic lateral sclerosis	0.0171	0.0663	CbGeAlD
Imipramine—Dental caries—Riluzole—amyotrophic lateral sclerosis	0.0166	0.0406	CcSEcCtD
Imipramine—Tongue discolouration—Riluzole—amyotrophic lateral sclerosis	0.0128	0.0313	CcSEcCtD
Imipramine—Bundle branch block—Riluzole—amyotrophic lateral sclerosis	0.0123	0.03	CcSEcCtD
Imipramine—Myoclonus—Riluzole—amyotrophic lateral sclerosis	0.0103	0.0251	CcSEcCtD
Imipramine—Delusion—Riluzole—amyotrophic lateral sclerosis	0.00876	0.0214	CcSEcCtD
Imipramine—Mania—Riluzole—amyotrophic lateral sclerosis	0.00853	0.0208	CcSEcCtD
Imipramine—Glaucoma—Riluzole—amyotrophic lateral sclerosis	0.00824	0.0201	CcSEcCtD
Imipramine—Extrapyramidal disorder—Riluzole—amyotrophic lateral sclerosis	0.00824	0.0201	CcSEcCtD
Imipramine—Ventricular fibrillation—Riluzole—amyotrophic lateral sclerosis	0.0081	0.0197	CcSEcCtD
Imipramine—KCND2—hindbrain—amyotrophic lateral sclerosis	0.00794	0.0308	CbGeAlD
Imipramine—Petechiae—Riluzole—amyotrophic lateral sclerosis	0.00754	0.0184	CcSEcCtD
Imipramine—Endocrine disorder—Riluzole—amyotrophic lateral sclerosis	0.00748	0.0182	CcSEcCtD
Imipramine—Delirium—Riluzole—amyotrophic lateral sclerosis	0.00721	0.0176	CcSEcCtD
Imipramine—HTR7—cranial nerve—amyotrophic lateral sclerosis	0.00715	0.0277	CbGeAlD
Imipramine—HTR7—pons—amyotrophic lateral sclerosis	0.00706	0.0274	CbGeAlD
Imipramine—KCND3—hindbrain—amyotrophic lateral sclerosis	0.00692	0.0268	CbGeAlD
Imipramine—Coordination abnormal—Riluzole—amyotrophic lateral sclerosis	0.00632	0.0154	CcSEcCtD
Imipramine—Ventricular tachycardia—Riluzole—amyotrophic lateral sclerosis	0.0062	0.0151	CcSEcCtD
Imipramine—Vascular purpura—Riluzole—amyotrophic lateral sclerosis	0.00503	0.0123	CcSEcCtD
Imipramine—Cardiac failure congestive—Riluzole—amyotrophic lateral sclerosis	0.00496	0.0121	CcSEcCtD
Imipramine—Libido decreased—Riluzole—amyotrophic lateral sclerosis	0.00486	0.0118	CcSEcCtD
Imipramine—SLC6A3—nerve—amyotrophic lateral sclerosis	0.00471	0.0183	CbGeAlD
Imipramine—HTR7—peripheral nervous system—amyotrophic lateral sclerosis	0.0047	0.0182	CbGeAlD
Imipramine—Purpura—Riluzole—amyotrophic lateral sclerosis	0.00467	0.0114	CcSEcCtD
Imipramine—Cardiac failure—Riluzole—amyotrophic lateral sclerosis	0.00461	0.0112	CcSEcCtD
Imipramine—KCND2—brainstem—amyotrophic lateral sclerosis	0.00455	0.0176	CbGeAlD
Imipramine—Disturbance in sexual arousal—Riluzole—amyotrophic lateral sclerosis	0.00447	0.0109	CcSEcCtD
Imipramine—HTR2A—cranial nerve—amyotrophic lateral sclerosis	0.00446	0.0173	CbGeAlD
Imipramine—Affect lability—Riluzole—amyotrophic lateral sclerosis	0.00443	0.0108	CcSEcCtD
Imipramine—HTR2A—pons—amyotrophic lateral sclerosis	0.0044	0.0171	CbGeAlD
Imipramine—Psychotic disorder—Riluzole—amyotrophic lateral sclerosis	0.0044	0.0107	CcSEcCtD
Imipramine—SLC22A3—tongue—amyotrophic lateral sclerosis	0.00433	0.0168	CbGeAlD
Imipramine—Urinary retention—Riluzole—amyotrophic lateral sclerosis	0.00428	0.0104	CcSEcCtD
Imipramine—Mood swings—Riluzole—amyotrophic lateral sclerosis	0.00427	0.0104	CcSEcCtD
Imipramine—Ataxia—Riluzole—amyotrophic lateral sclerosis	0.00423	0.0103	CcSEcCtD
Imipramine—Liver function test abnormal—Riluzole—amyotrophic lateral sclerosis	0.00416	0.0101	CcSEcCtD
Imipramine—Orthostatic hypotension—Riluzole—amyotrophic lateral sclerosis	0.00411	0.01	CcSEcCtD
Imipramine—Breast disorder—Riluzole—amyotrophic lateral sclerosis	0.00407	0.00992	CcSEcCtD
Imipramine—KCND3—brainstem—amyotrophic lateral sclerosis	0.00397	0.0154	CbGeAlD
Imipramine—SLC6A2—nerve—amyotrophic lateral sclerosis	0.0038	0.0147	CbGeAlD
Imipramine—HTR2A—hindlimb—amyotrophic lateral sclerosis	0.00376	0.0146	CbGeAlD
Imipramine—Pancytopenia—Riluzole—amyotrophic lateral sclerosis	0.0037	0.00901	CcSEcCtD
Imipramine—HTR7—nerve—amyotrophic lateral sclerosis	0.00366	0.0142	CbGeAlD
Imipramine—Pollakiuria—Riluzole—amyotrophic lateral sclerosis	0.00359	0.00876	CcSEcCtD
Imipramine—Erectile dysfunction—Riluzole—amyotrophic lateral sclerosis	0.00358	0.00873	CcSEcCtD
Imipramine—Photosensitivity reaction—Riluzole—amyotrophic lateral sclerosis	0.00355	0.00866	CcSEcCtD
Imipramine—Weight increased—Riluzole—amyotrophic lateral sclerosis	0.00354	0.00863	CcSEcCtD
Imipramine—SLC6A3—hindbrain—amyotrophic lateral sclerosis	0.00353	0.0137	CbGeAlD
Imipramine—Weight decreased—Riluzole—amyotrophic lateral sclerosis	0.00352	0.00858	CcSEcCtD
Imipramine—Infestation NOS—Riluzole—amyotrophic lateral sclerosis	0.00347	0.00846	CcSEcCtD
Imipramine—Infestation—Riluzole—amyotrophic lateral sclerosis	0.00347	0.00846	CcSEcCtD
Imipramine—DRD2—nerve—amyotrophic lateral sclerosis	0.00346	0.0134	CbGeAlD
Imipramine—Acute coronary syndrome—Riluzole—amyotrophic lateral sclerosis	0.00342	0.00834	CcSEcCtD
Imipramine—Myocardial infarction—Riluzole—amyotrophic lateral sclerosis	0.0034	0.00829	CcSEcCtD
Imipramine—Neuropathy peripheral—Riluzole—amyotrophic lateral sclerosis	0.0034	0.00829	CcSEcCtD
Imipramine—Stomatitis—Riluzole—amyotrophic lateral sclerosis	0.00338	0.00824	CcSEcCtD
Imipramine—Jaundice—Riluzole—amyotrophic lateral sclerosis	0.00338	0.00824	CcSEcCtD
Imipramine—Hepatobiliary disease—Riluzole—amyotrophic lateral sclerosis	0.00328	0.008	CcSEcCtD
Imipramine—Agranulocytosis—Riluzole—amyotrophic lateral sclerosis	0.00324	0.00789	CcSEcCtD
Imipramine—SLC6A4—hindbrain—amyotrophic lateral sclerosis	0.00323	0.0125	CbGeAlD
Imipramine—HTR2A—appendage—amyotrophic lateral sclerosis	0.00322	0.0125	CbGeAlD
Imipramine—KCND2—medulla oblongata—amyotrophic lateral sclerosis	0.00317	0.0123	CbGeAlD
Imipramine—Hepatitis—Riluzole—amyotrophic lateral sclerosis	0.00311	0.00759	CcSEcCtD
Imipramine—Hallucination—Riluzole—amyotrophic lateral sclerosis	0.0031	0.00755	CcSEcCtD
Imipramine—Hypoaesthesia—Riluzole—amyotrophic lateral sclerosis	0.0031	0.00755	CcSEcCtD
Imipramine—Urinary tract disorder—Riluzole—amyotrophic lateral sclerosis	0.00308	0.0075	CcSEcCtD
Imipramine—Urethral disorder—Riluzole—amyotrophic lateral sclerosis	0.00305	0.00744	CcSEcCtD
Imipramine—HTR2A—peripheral nervous system—amyotrophic lateral sclerosis	0.00293	0.0114	CbGeAlD
Imipramine—Eye disorder—Riluzole—amyotrophic lateral sclerosis	0.00291	0.00709	CcSEcCtD
Imipramine—Cardiac disorder—Riluzole—amyotrophic lateral sclerosis	0.00289	0.00704	CcSEcCtD
Imipramine—HTR1A—hindbrain—amyotrophic lateral sclerosis	0.00287	0.0111	CbGeAlD
Imipramine—KCND2—spinal cord—amyotrophic lateral sclerosis	0.00283	0.011	CbGeAlD
Imipramine—Angiopathy—Riluzole—amyotrophic lateral sclerosis	0.00283	0.00689	CcSEcCtD
Imipramine—Immune system disorder—Riluzole—amyotrophic lateral sclerosis	0.00281	0.00686	CcSEcCtD
Imipramine—Mediastinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00281	0.00684	CcSEcCtD
Imipramine—Arrhythmia—Riluzole—amyotrophic lateral sclerosis	0.00278	0.00678	CcSEcCtD
Imipramine—Alopecia—Riluzole—amyotrophic lateral sclerosis	0.00275	0.00671	CcSEcCtD
Imipramine—HTR7—hindbrain—amyotrophic lateral sclerosis	0.00274	0.0106	CbGeAlD
Imipramine—Mental disorder—Riluzole—amyotrophic lateral sclerosis	0.00273	0.00665	CcSEcCtD
Imipramine—Malnutrition—Riluzole—amyotrophic lateral sclerosis	0.00271	0.00661	CcSEcCtD
Imipramine—Tension—Riluzole—amyotrophic lateral sclerosis	0.00266	0.00648	CcSEcCtD
Imipramine—Dysgeusia—Riluzole—amyotrophic lateral sclerosis	0.00266	0.00647	CcSEcCtD
Imipramine—ADRA1A—hindbrain—amyotrophic lateral sclerosis	0.00265	0.0103	CbGeAlD
Imipramine—Nervousness—Riluzole—amyotrophic lateral sclerosis	0.00263	0.00642	CcSEcCtD
Imipramine—DRD2—hindbrain—amyotrophic lateral sclerosis	0.00259	0.0101	CbGeAlD
Imipramine—Tremor—Riluzole—amyotrophic lateral sclerosis	0.00254	0.00619	CcSEcCtD
Imipramine—Ill-defined disorder—Riluzole—amyotrophic lateral sclerosis	0.00252	0.00613	CcSEcCtD
Imipramine—Agitation—Riluzole—amyotrophic lateral sclerosis	0.00249	0.00607	CcSEcCtD
Imipramine—Malaise—Riluzole—amyotrophic lateral sclerosis	0.00245	0.00596	CcSEcCtD
Imipramine—Syncope—Riluzole—amyotrophic lateral sclerosis	0.00243	0.00593	CcSEcCtD
Imipramine—Leukopenia—Riluzole—amyotrophic lateral sclerosis	0.00243	0.00591	CcSEcCtD
Imipramine—Palpitations—Riluzole—amyotrophic lateral sclerosis	0.0024	0.00584	CcSEcCtD
Imipramine—KCND2—nervous system—amyotrophic lateral sclerosis	0.00238	0.00924	CbGeAlD
Imipramine—Loss of consciousness—Riluzole—amyotrophic lateral sclerosis	0.00238	0.00581	CcSEcCtD
Imipramine—Convulsion—Riluzole—amyotrophic lateral sclerosis	0.00235	0.00573	CcSEcCtD
Imipramine—Hypertension—Riluzole—amyotrophic lateral sclerosis	0.00234	0.00571	CcSEcCtD
Imipramine—Anxiety—Riluzole—amyotrophic lateral sclerosis	0.0023	0.00561	CcSEcCtD
Imipramine—KCND2—central nervous system—amyotrophic lateral sclerosis	0.0023	0.0089	CbGeAlD
Imipramine—Unspecified disorder of skin and subcutaneous tissue—Riluzole—amyotrophic lateral sclerosis	0.00229	0.00559	CcSEcCtD
Imipramine—HTR2A—nerve—amyotrophic lateral sclerosis	0.00228	0.00886	CbGeAlD
Imipramine—Discomfort—Riluzole—amyotrophic lateral sclerosis	0.00228	0.00556	CcSEcCtD
Imipramine—Dry mouth—Riluzole—amyotrophic lateral sclerosis	0.00226	0.0055	CcSEcCtD
Imipramine—KCND2—cerebellum—amyotrophic lateral sclerosis	0.00224	0.0087	CbGeAlD
Imipramine—Confusional state—Riluzole—amyotrophic lateral sclerosis	0.00223	0.00544	CcSEcCtD
Imipramine—Oedema—Riluzole—amyotrophic lateral sclerosis	0.00221	0.00539	CcSEcCtD
Imipramine—Anaphylactic shock—Riluzole—amyotrophic lateral sclerosis	0.00221	0.00539	CcSEcCtD
Imipramine—Infection—Riluzole—amyotrophic lateral sclerosis	0.0022	0.00536	CcSEcCtD
Imipramine—Shock—Riluzole—amyotrophic lateral sclerosis	0.00218	0.00531	CcSEcCtD
Imipramine—Nervous system disorder—Riluzole—amyotrophic lateral sclerosis	0.00217	0.00529	CcSEcCtD
Imipramine—Thrombocytopenia—Riluzole—amyotrophic lateral sclerosis	0.00217	0.00528	CcSEcCtD
Imipramine—Tachycardia—Riluzole—amyotrophic lateral sclerosis	0.00216	0.00526	CcSEcCtD
Imipramine—Skin disorder—Riluzole—amyotrophic lateral sclerosis	0.00215	0.00524	CcSEcCtD
Imipramine—Hyperhidrosis—Riluzole—amyotrophic lateral sclerosis	0.00214	0.00521	CcSEcCtD
Imipramine—Anorexia—Riluzole—amyotrophic lateral sclerosis	0.00211	0.00514	CcSEcCtD
Imipramine—KCND3—nervous system—amyotrophic lateral sclerosis	0.00208	0.00806	CbGeAlD
Imipramine—SLC22A3—embryo—amyotrophic lateral sclerosis	0.00208	0.00805	CbGeAlD
Imipramine—SLC6A3—brainstem—amyotrophic lateral sclerosis	0.00202	0.00784	CbGeAlD
Imipramine—Insomnia—Riluzole—amyotrophic lateral sclerosis	0.002	0.00488	CcSEcCtD
Imipramine—KCND3—central nervous system—amyotrophic lateral sclerosis	0.002	0.00776	CbGeAlD
Imipramine—Paraesthesia—Riluzole—amyotrophic lateral sclerosis	0.00199	0.00484	CcSEcCtD
Imipramine—CHRM4—nervous system—amyotrophic lateral sclerosis	0.00198	0.00768	CbGeAlD
Imipramine—Somnolence—Riluzole—amyotrophic lateral sclerosis	0.00197	0.00479	CcSEcCtD
Imipramine—KCND3—cerebellum—amyotrophic lateral sclerosis	0.00196	0.00758	CbGeAlD
Imipramine—HTR2C—brainstem—amyotrophic lateral sclerosis	0.00195	0.00758	CbGeAlD
Imipramine—Dyspepsia—Riluzole—amyotrophic lateral sclerosis	0.00195	0.00475	CcSEcCtD
Imipramine—Decreased appetite—Riluzole—amyotrophic lateral sclerosis	0.00192	0.00469	CcSEcCtD
Imipramine—Gastrointestinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00191	0.00466	CcSEcCtD
Imipramine—Fatigue—Riluzole—amyotrophic lateral sclerosis	0.00191	0.00465	CcSEcCtD
Imipramine—CHRM4—central nervous system—amyotrophic lateral sclerosis	0.00191	0.00739	CbGeAlD
Imipramine—Constipation—Riluzole—amyotrophic lateral sclerosis	0.00189	0.00461	CcSEcCtD
Imipramine—SLC6A4—brainstem—amyotrophic lateral sclerosis	0.00185	0.00718	CbGeAlD
Imipramine—Feeling abnormal—Riluzole—amyotrophic lateral sclerosis	0.00182	0.00444	CcSEcCtD
Imipramine—KCND2—brain—amyotrophic lateral sclerosis	0.00182	0.00707	CbGeAlD
Imipramine—Gastrointestinal pain—Riluzole—amyotrophic lateral sclerosis	0.00181	0.00441	CcSEcCtD
Imipramine—HTR6—nervous system—amyotrophic lateral sclerosis	0.00177	0.00687	CbGeAlD
Imipramine—Urticaria—Riluzole—amyotrophic lateral sclerosis	0.00176	0.00428	CcSEcCtD
Imipramine—Abdominal pain—Riluzole—amyotrophic lateral sclerosis	0.00175	0.00426	CcSEcCtD
Imipramine—Body temperature increased—Riluzole—amyotrophic lateral sclerosis	0.00175	0.00426	CcSEcCtD
Imipramine—HTR2A—hindbrain—amyotrophic lateral sclerosis	0.00171	0.00663	CbGeAlD
Imipramine—HTR6—central nervous system—amyotrophic lateral sclerosis	0.00171	0.00661	CbGeAlD
Imipramine—HTR1A—brainstem—amyotrophic lateral sclerosis	0.00165	0.00638	CbGeAlD
Imipramine—SLC6A2—brainstem—amyotrophic lateral sclerosis	0.00163	0.00632	CbGeAlD
Imipramine—KCND3—brain—amyotrophic lateral sclerosis	0.00159	0.00616	CbGeAlD
Imipramine—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.00159	0.00387	CcSEcCtD
Imipramine—HTR7—brainstem—amyotrophic lateral sclerosis	0.00157	0.0061	CbGeAlD
Imipramine—Pruritus—Riluzole—amyotrophic lateral sclerosis	0.00157	0.00382	CcSEcCtD
Imipramine—CYP2D6—hindbrain—amyotrophic lateral sclerosis	0.00156	0.00604	CbGeAlD
Imipramine—CHRM5—nervous system—amyotrophic lateral sclerosis	0.00155	0.006	CbGeAlD
Imipramine—ADRA1A—brainstem—amyotrophic lateral sclerosis	0.00152	0.00588	CbGeAlD
Imipramine—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.00151	0.00369	CcSEcCtD
Imipramine—CHRM4—brain—amyotrophic lateral sclerosis	0.00151	0.00587	CbGeAlD
Imipramine—CHRM5—central nervous system—amyotrophic lateral sclerosis	0.00149	0.00578	CbGeAlD
Imipramine—DRD2—brainstem—amyotrophic lateral sclerosis	0.00149	0.00576	CbGeAlD
Imipramine—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.00146	0.00357	CcSEcCtD
Imipramine—ADRA1B—nervous system—amyotrophic lateral sclerosis	0.00141	0.00548	CbGeAlD
Imipramine—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.00141	0.00343	CcSEcCtD
Imipramine—Rash—Riluzole—amyotrophic lateral sclerosis	0.0014	0.0034	CcSEcCtD
Imipramine—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.00139	0.0034	CcSEcCtD
Imipramine—Headache—Riluzole—amyotrophic lateral sclerosis	0.00139	0.00338	CcSEcCtD
Imipramine—ADRA1D—nervous system—amyotrophic lateral sclerosis	0.00138	0.00536	CbGeAlD
Imipramine—HTR2C—medulla oblongata—amyotrophic lateral sclerosis	0.00136	0.00528	CbGeAlD
Imipramine—ADRA1B—central nervous system—amyotrophic lateral sclerosis	0.00136	0.00528	CbGeAlD
Imipramine—HTR6—brain—amyotrophic lateral sclerosis	0.00135	0.00525	CbGeAlD
Imipramine—ORM1—spinal cord—amyotrophic lateral sclerosis	0.00135	0.00524	CbGeAlD
Imipramine—ADRA1D—central nervous system—amyotrophic lateral sclerosis	0.00133	0.00516	CbGeAlD
Imipramine—Nausea—Riluzole—amyotrophic lateral sclerosis	0.00131	0.0032	CcSEcCtD
Imipramine—SLC22A4—spinal cord—amyotrophic lateral sclerosis	0.0013	0.00504	CbGeAlD
Imipramine—SLC6A3—spinal cord—amyotrophic lateral sclerosis	0.00126	0.00487	CbGeAlD
Imipramine—HTR2C—spinal cord—amyotrophic lateral sclerosis	0.00122	0.00471	CbGeAlD
Imipramine—CHRM5—brain—amyotrophic lateral sclerosis	0.00118	0.00459	CbGeAlD
Imipramine—SLC6A4—spinal cord—amyotrophic lateral sclerosis	0.00115	0.00447	CbGeAlD
Imipramine—ORM1—nervous system—amyotrophic lateral sclerosis	0.00114	0.00442	CbGeAlD
Imipramine—SLC6A2—medulla oblongata—amyotrophic lateral sclerosis	0.00114	0.00441	CbGeAlD
Imipramine—ORM1—central nervous system—amyotrophic lateral sclerosis	0.0011	0.00425	CbGeAlD
Imipramine—HTR7—medulla oblongata—amyotrophic lateral sclerosis	0.0011	0.00425	CbGeAlD
Imipramine—ADRA1B—brain—amyotrophic lateral sclerosis	0.00108	0.00419	CbGeAlD
Imipramine—HTR2A—embryo—amyotrophic lateral sclerosis	0.00107	0.00415	CbGeAlD
Imipramine—CHRM2—nervous system—amyotrophic lateral sclerosis	0.00106	0.00412	CbGeAlD
Imipramine—SLC6A3—nervous system—amyotrophic lateral sclerosis	0.00106	0.00411	CbGeAlD
Imipramine—ADRA1D—brain—amyotrophic lateral sclerosis	0.00106	0.0041	CbGeAlD
Imipramine—SLC22A1—nervous system—amyotrophic lateral sclerosis	0.00104	0.00405	CbGeAlD
Imipramine—SLC22A4—cerebellum—amyotrophic lateral sclerosis	0.00103	0.004	CbGeAlD
Imipramine—HTR2C—nervous system—amyotrophic lateral sclerosis	0.00102	0.00397	CbGeAlD
Imipramine—HTR1A—spinal cord—amyotrophic lateral sclerosis	0.00102	0.00397	CbGeAlD
Imipramine—CHRM2—central nervous system—amyotrophic lateral sclerosis	0.00102	0.00397	CbGeAlD
Imipramine—KCNH2—medulla oblongata—amyotrophic lateral sclerosis	0.00102	0.00396	CbGeAlD
Imipramine—SLC6A3—central nervous system—amyotrophic lateral sclerosis	0.00102	0.00395	CbGeAlD
Imipramine—SLC22A1—central nervous system—amyotrophic lateral sclerosis	0.001	0.0039	CbGeAlD
Imipramine—SLC22A3—nervous system—amyotrophic lateral sclerosis	0.000997	0.00387	CbGeAlD
Imipramine—SLC6A3—cerebellum—amyotrophic lateral sclerosis	0.000997	0.00387	CbGeAlD
Imipramine—HTR2C—central nervous system—amyotrophic lateral sclerosis	0.000986	0.00382	CbGeAlD
Imipramine—HTR2A—brainstem—amyotrophic lateral sclerosis	0.00098	0.0038	CbGeAlD
Imipramine—HTR7—spinal cord—amyotrophic lateral sclerosis	0.000978	0.00379	CbGeAlD
Imipramine—SLC6A4—nervous system—amyotrophic lateral sclerosis	0.000971	0.00376	CbGeAlD
Imipramine—CHRM1—nervous system—amyotrophic lateral sclerosis	0.000967	0.00375	CbGeAlD
Imipramine—SLC22A3—central nervous system—amyotrophic lateral sclerosis	0.00096	0.00372	CbGeAlD
Imipramine—SLC6A4—central nervous system—amyotrophic lateral sclerosis	0.000935	0.00362	CbGeAlD
Imipramine—CHRM1—central nervous system—amyotrophic lateral sclerosis	0.000931	0.00361	CbGeAlD
Imipramine—KCNH2—spinal cord—amyotrophic lateral sclerosis	0.000911	0.00353	CbGeAlD
Imipramine—CYP2D6—brainstem—amyotrophic lateral sclerosis	0.000893	0.00346	CbGeAlD
Imipramine—CHRM3—nervous system—amyotrophic lateral sclerosis	0.000865	0.00336	CbGeAlD
Imipramine—HTR1A—nervous system—amyotrophic lateral sclerosis	0.000862	0.00334	CbGeAlD
Imipramine—SLC6A2—nervous system—amyotrophic lateral sclerosis	0.000855	0.00331	CbGeAlD
Imipramine—SLC22A4—brain—amyotrophic lateral sclerosis	0.000838	0.00325	CbGeAlD
Imipramine—CHRM3—central nervous system—amyotrophic lateral sclerosis	0.000833	0.00323	CbGeAlD
Imipramine—HTR1A—central nervous system—amyotrophic lateral sclerosis	0.00083	0.00322	CbGeAlD
Imipramine—HTR7—nervous system—amyotrophic lateral sclerosis	0.000824	0.00319	CbGeAlD
Imipramine—SLC6A2—central nervous system—amyotrophic lateral sclerosis	0.000823	0.00319	CbGeAlD
Imipramine—CHRM2—brain—amyotrophic lateral sclerosis	0.000812	0.00315	CbGeAlD
Imipramine—HTR1A—cerebellum—amyotrophic lateral sclerosis	0.000811	0.00314	CbGeAlD
Imipramine—SLC6A3—brain—amyotrophic lateral sclerosis	0.00081	0.00314	CbGeAlD
Imipramine—SLC22A1—brain—amyotrophic lateral sclerosis	0.000798	0.00309	CbGeAlD
Imipramine—ADRA1A—nervous system—amyotrophic lateral sclerosis	0.000795	0.00308	CbGeAlD
Imipramine—HTR7—central nervous system—amyotrophic lateral sclerosis	0.000793	0.00307	CbGeAlD
Imipramine—CYP2E1—medulla oblongata—amyotrophic lateral sclerosis	0.000787	0.00305	CbGeAlD
Imipramine—HTR2C—brain—amyotrophic lateral sclerosis	0.000783	0.00303	CbGeAlD
Imipramine—DRD2—nervous system—amyotrophic lateral sclerosis	0.000779	0.00302	CbGeAlD
Imipramine—HTR7—cerebellum—amyotrophic lateral sclerosis	0.000775	0.00301	CbGeAlD
Imipramine—KCNH2—nervous system—amyotrophic lateral sclerosis	0.000767	0.00298	CbGeAlD
Imipramine—ADRA1A—central nervous system—amyotrophic lateral sclerosis	0.000765	0.00297	CbGeAlD
Imipramine—SLC22A3—brain—amyotrophic lateral sclerosis	0.000762	0.00296	CbGeAlD
Imipramine—DRD2—central nervous system—amyotrophic lateral sclerosis	0.00075	0.00291	CbGeAlD
Imipramine—ADRA1A—cerebellum—amyotrophic lateral sclerosis	0.000748	0.0029	CbGeAlD
Imipramine—SLC6A4—brain—amyotrophic lateral sclerosis	0.000742	0.00288	CbGeAlD
Imipramine—CHRM1—brain—amyotrophic lateral sclerosis	0.000739	0.00287	CbGeAlD
Imipramine—KCNH2—central nervous system—amyotrophic lateral sclerosis	0.000739	0.00286	CbGeAlD
Imipramine—DRD2—cerebellum—amyotrophic lateral sclerosis	0.000733	0.00284	CbGeAlD
Imipramine—KCNH2—cerebellum—amyotrophic lateral sclerosis	0.000722	0.0028	CbGeAlD
Imipramine—CYP2E1—spinal cord—amyotrophic lateral sclerosis	0.000701	0.00272	CbGeAlD
Imipramine—ABCB1—embryo—amyotrophic lateral sclerosis	0.000701	0.00272	CbGeAlD
Imipramine—HTR2A—medulla oblongata—amyotrophic lateral sclerosis	0.000684	0.00265	CbGeAlD
Imipramine—CHRM3—brain—amyotrophic lateral sclerosis	0.000661	0.00256	CbGeAlD
Imipramine—HTR1A—brain—amyotrophic lateral sclerosis	0.000659	0.00255	CbGeAlD
Imipramine—SLC6A2—brain—amyotrophic lateral sclerosis	0.000653	0.00253	CbGeAlD
Imipramine—CYP2B6—nervous system—amyotrophic lateral sclerosis	0.00063	0.00244	CbGeAlD
Imipramine—HTR7—brain—amyotrophic lateral sclerosis	0.00063	0.00244	CbGeAlD
Imipramine—HRH1—nervous system—amyotrophic lateral sclerosis	0.000615	0.00238	CbGeAlD
Imipramine—HTR2A—spinal cord—amyotrophic lateral sclerosis	0.00061	0.00236	CbGeAlD
Imipramine—ADRA1A—brain—amyotrophic lateral sclerosis	0.000607	0.00235	CbGeAlD
Imipramine—CYP2B6—central nervous system—amyotrophic lateral sclerosis	0.000606	0.00235	CbGeAlD
Imipramine—DRD2—brain—amyotrophic lateral sclerosis	0.000595	0.00231	CbGeAlD
Imipramine—HRH1—central nervous system—amyotrophic lateral sclerosis	0.000592	0.0023	CbGeAlD
Imipramine—CYP2E1—nervous system—amyotrophic lateral sclerosis	0.000591	0.00229	CbGeAlD
Imipramine—KCNH2—brain—amyotrophic lateral sclerosis	0.000587	0.00227	CbGeAlD
Imipramine—CYP2E1—central nervous system—amyotrophic lateral sclerosis	0.000569	0.00221	CbGeAlD
Imipramine—CYP2E1—cerebellum—amyotrophic lateral sclerosis	0.000556	0.00216	CbGeAlD
Imipramine—HTR2A—nervous system—amyotrophic lateral sclerosis	0.000514	0.00199	CbGeAlD
Imipramine—HTR2A—central nervous system—amyotrophic lateral sclerosis	0.000495	0.00192	CbGeAlD
Imipramine—HTR2A—cerebellum—amyotrophic lateral sclerosis	0.000483	0.00187	CbGeAlD
Imipramine—CYP2B6—brain—amyotrophic lateral sclerosis	0.000481	0.00187	CbGeAlD
Imipramine—CYP3A4—nervous system—amyotrophic lateral sclerosis	0.000476	0.00184	CbGeAlD
Imipramine—HRH1—brain—amyotrophic lateral sclerosis	0.00047	0.00182	CbGeAlD
Imipramine—CYP2D6—nervous system—amyotrophic lateral sclerosis	0.000468	0.00181	CbGeAlD
Imipramine—CYP3A4—central nervous system—amyotrophic lateral sclerosis	0.000458	0.00178	CbGeAlD
Imipramine—CYP2E1—brain—amyotrophic lateral sclerosis	0.000452	0.00175	CbGeAlD
Imipramine—CYP2D6—central nervous system—amyotrophic lateral sclerosis	0.000451	0.00175	CbGeAlD
Imipramine—ABCB1—medulla oblongata—amyotrophic lateral sclerosis	0.000448	0.00174	CbGeAlD
Imipramine—CYP2D6—cerebellum—amyotrophic lateral sclerosis	0.00044	0.00171	CbGeAlD
Imipramine—ABCB1—spinal cord—amyotrophic lateral sclerosis	0.0004	0.00155	CbGeAlD
Imipramine—HTR2A—brain—amyotrophic lateral sclerosis	0.000393	0.00152	CbGeAlD
Imipramine—Amitriptyline—SIGMAR1—amyotrophic lateral sclerosis	0.000377	0.591	CrCbGaD
Imipramine—CYP2D6—brain—amyotrophic lateral sclerosis	0.000358	0.00139	CbGeAlD
Imipramine—ABCB1—nervous system—amyotrophic lateral sclerosis	0.000337	0.00131	CbGeAlD
Imipramine—ABCB1—central nervous system—amyotrophic lateral sclerosis	0.000324	0.00126	CbGeAlD
Imipramine—ABCB1—cerebellum—amyotrophic lateral sclerosis	0.000317	0.00123	CbGeAlD
Imipramine—Clomipramine—GSTP1—amyotrophic lateral sclerosis	0.00026	0.409	CrCbGaD
Imipramine—ABCB1—brain—amyotrophic lateral sclerosis	0.000257	0.000998	CbGeAlD
Imipramine—CYP2C18—Metabolism—APOE—amyotrophic lateral sclerosis	3.24e-05	0.000192	CbGpPWpGaD
Imipramine—HTR2A—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	3.21e-05	0.00019	CbGpPWpGaD
Imipramine—HRH1—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	3.21e-05	0.00019	CbGpPWpGaD
Imipramine—CHRM1—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	3.2e-05	0.000189	CbGpPWpGaD
Imipramine—CHRM3—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	3.19e-05	0.000188	CbGpPWpGaD
Imipramine—DRD2—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	3.18e-05	0.000188	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	3.16e-05	0.000187	CbGpPWpGaD
Imipramine—CHRM2—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	3.16e-05	0.000187	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	3.16e-05	0.000187	CbGpPWpGaD
Imipramine—ADRA1A—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	3.15e-05	0.000186	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	3.13e-05	0.000185	CbGpPWpGaD
Imipramine—ADRA1B—Signaling by GPCR—C3—amyotrophic lateral sclerosis	3.13e-05	0.000185	CbGpPWpGaD
Imipramine—HTR2A—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	3.13e-05	0.000185	CbGpPWpGaD
Imipramine—HRH1—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	3.12e-05	0.000185	CbGpPWpGaD
Imipramine—CHRM1—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	3.11e-05	0.000184	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—DAO—amyotrophic lateral sclerosis	3.1e-05	0.000183	CbGpPWpGaD
Imipramine—CHRM3—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	3.1e-05	0.000183	CbGpPWpGaD
Imipramine—CHRM2—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	3.07e-05	0.000182	CbGpPWpGaD
Imipramine—ADRA1A—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	3.06e-05	0.000181	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	3.06e-05	0.000181	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—PLB1—amyotrophic lateral sclerosis	3.05e-05	0.00018	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	3.04e-05	0.00018	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	2.98e-05	0.000176	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	2.97e-05	0.000176	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	2.97e-05	0.000175	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—CHAT—amyotrophic lateral sclerosis	2.96e-05	0.000175	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	2.91e-05	0.000172	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—CHAT—amyotrophic lateral sclerosis	2.89e-05	0.000171	CbGpPWpGaD
Imipramine—DRD2—Signaling by GPCR—C3—amyotrophic lateral sclerosis	2.89e-05	0.000171	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	2.87e-05	0.00017	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	2.85e-05	0.000169	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	2.85e-05	0.000169	CbGpPWpGaD
Imipramine—CYP3A7—Metabolism—GSTP1—amyotrophic lateral sclerosis	2.85e-05	0.000169	CbGpPWpGaD
Imipramine—SLC22A2—Metabolism—GSTP1—amyotrophic lateral sclerosis	2.85e-05	0.000168	CbGpPWpGaD
Imipramine—HTR2A—Signaling by GPCR—C3—amyotrophic lateral sclerosis	2.84e-05	0.000168	CbGpPWpGaD
Imipramine—HRH1—Signaling by GPCR—C3—amyotrophic lateral sclerosis	2.84e-05	0.000168	CbGpPWpGaD
Imipramine—CHRM1—Signaling by GPCR—C3—amyotrophic lateral sclerosis	2.83e-05	0.000167	CbGpPWpGaD
Imipramine—CHRM3—Signaling by GPCR—C3—amyotrophic lateral sclerosis	2.82e-05	0.000167	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—GSR—amyotrophic lateral sclerosis	2.81e-05	0.000166	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	2.8e-05	0.000166	CbGpPWpGaD
Imipramine—CHRM2—Signaling by GPCR—C3—amyotrophic lateral sclerosis	2.79e-05	0.000165	CbGpPWpGaD
Imipramine—ADRA1A—Signaling by GPCR—C3—amyotrophic lateral sclerosis	2.78e-05	0.000164	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	2.73e-05	0.000162	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	2.73e-05	0.000161	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—CHAT—amyotrophic lateral sclerosis	2.73e-05	0.000161	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	2.72e-05	0.000161	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	2.7e-05	0.00016	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	2.69e-05	0.000159	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	2.68e-05	0.000159	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	2.68e-05	0.000159	CbGpPWpGaD
Imipramine—SLC22A1—Metabolism—GSTP1—amyotrophic lateral sclerosis	2.65e-05	0.000157	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	2.64e-05	0.000156	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	2.64e-05	0.000156	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	2.63e-05	0.000155	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—C3—amyotrophic lateral sclerosis	2.62e-05	0.000155	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—C3—amyotrophic lateral sclerosis	2.62e-05	0.000155	CbGpPWpGaD
Imipramine—CYP3A7—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	2.62e-05	0.000155	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	2.62e-05	0.000155	CbGpPWpGaD
Imipramine—SLC22A2—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	2.62e-05	0.000155	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	2.6e-05	0.000154	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	2.59e-05	0.000153	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	2.59e-05	0.000153	CbGpPWpGaD
Imipramine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	2.58e-05	0.000152	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	2.56e-05	0.000151	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	2.52e-05	0.000149	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	2.52e-05	0.000149	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	2.48e-05	0.000147	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—C3—amyotrophic lateral sclerosis	2.48e-05	0.000146	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	2.47e-05	0.000146	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	2.46e-05	0.000146	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	2.46e-05	0.000145	CbGpPWpGaD
Imipramine—CHRM3—Metabolism—GSTP1—amyotrophic lateral sclerosis	2.45e-05	0.000145	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—APOE—amyotrophic lateral sclerosis	2.44e-05	0.000144	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—APOE—amyotrophic lateral sclerosis	2.44e-05	0.000144	CbGpPWpGaD
Imipramine—SLC22A1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	2.44e-05	0.000144	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	2.43e-05	0.000144	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	2.43e-05	0.000143	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	2.4e-05	0.000142	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—C3—amyotrophic lateral sclerosis	2.37e-05	0.00014	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	2.36e-05	0.00014	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	2.35e-05	0.000139	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—PLB1—amyotrophic lateral sclerosis	2.35e-05	0.000139	CbGpPWpGaD
Imipramine—SLC22A3—Metabolism—PTGS2—amyotrophic lateral sclerosis	2.35e-05	0.000139	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	2.35e-05	0.000139	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	2.34e-05	0.000138	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	2.34e-05	0.000138	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	2.33e-05	0.000138	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	2.32e-05	0.000137	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	2.31e-05	0.000137	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—CHAT—amyotrophic lateral sclerosis	2.31e-05	0.000137	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—APOE—amyotrophic lateral sclerosis	2.3e-05	0.000136	CbGpPWpGaD
Imipramine—CHRM3—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	2.25e-05	0.000133	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—C3—amyotrophic lateral sclerosis	2.23e-05	0.000132	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	2.23e-05	0.000132	CbGpPWpGaD
Imipramine—CYP2C18—Metabolism—PTGS2—amyotrophic lateral sclerosis	2.22e-05	0.000131	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—APOE—amyotrophic lateral sclerosis	2.21e-05	0.000131	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	2.2e-05	0.00013	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	2.19e-05	0.000129	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—GSR—amyotrophic lateral sclerosis	2.17e-05	0.000128	CbGpPWpGaD
Imipramine—CYP3A7—Metabolism—APOE—amyotrophic lateral sclerosis	2.16e-05	0.000127	CbGpPWpGaD
Imipramine—SLC22A2—Metabolism—APOE—amyotrophic lateral sclerosis	2.15e-05	0.000127	CbGpPWpGaD
Imipramine—CYP2B6—Metabolism—GSTP1—amyotrophic lateral sclerosis	2.11e-05	0.000125	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	2.11e-05	0.000125	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	2.09e-05	0.000124	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—APOE—amyotrophic lateral sclerosis	2.08e-05	0.000123	CbGpPWpGaD
Imipramine—CYP2E1—Metabolism—GSTP1—amyotrophic lateral sclerosis	2.06e-05	0.000122	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	2.05e-05	0.000121	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	2.02e-05	0.000119	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	2.02e-05	0.000119	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	2.02e-05	0.000119	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	2.02e-05	0.000119	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	2.01e-05	0.000119	CbGpPWpGaD
Imipramine—SLC22A1—Metabolism—APOE—amyotrophic lateral sclerosis	2.01e-05	0.000119	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	2e-05	0.000118	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.98e-05	0.000117	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.98e-05	0.000117	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.94e-05	0.000115	CbGpPWpGaD
Imipramine—CYP2B6—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.94e-05	0.000115	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.93e-05	0.000114	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.93e-05	0.000114	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.9e-05	0.000113	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.9e-05	0.000112	CbGpPWpGaD
Imipramine—CYP2E1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.9e-05	0.000112	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.9e-05	0.000112	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.89e-05	0.000112	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.88e-05	0.000111	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.86e-05	0.00011	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.86e-05	0.00011	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	1.85e-05	0.00011	CbGpPWpGaD
Imipramine—CHRM3—Metabolism—APOE—amyotrophic lateral sclerosis	1.85e-05	0.00011	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.85e-05	0.000109	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.82e-05	0.000108	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.81e-05	0.000107	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.8e-05	0.000106	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—CHAT—amyotrophic lateral sclerosis	1.78e-05	0.000105	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.72e-05	0.000102	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.71e-05	0.000101	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.71e-05	0.000101	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.68e-05	9.92e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.67e-05	9.9e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.67e-05	9.87e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.66e-05	9.84e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.65e-05	9.74e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.64e-05	9.72e-05	CbGpPWpGaD
Imipramine—CYP2B6—Metabolism—APOE—amyotrophic lateral sclerosis	1.59e-05	9.42e-05	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.59e-05	9.42e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.59e-05	9.39e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.56e-05	9.24e-05	CbGpPWpGaD
Imipramine—CYP2E1—Metabolism—APOE—amyotrophic lateral sclerosis	1.56e-05	9.23e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.56e-05	9.22e-05	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.55e-05	9.19e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.55e-05	9.19e-05	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.55e-05	9.19e-05	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.55e-05	9.18e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.55e-05	9.16e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.53e-05	9.07e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.53e-05	9.05e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.49e-05	8.84e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.49e-05	8.79e-05	CbGpPWpGaD
Imipramine—CYP3A7—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.48e-05	8.73e-05	CbGpPWpGaD
Imipramine—SLC22A2—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.47e-05	8.72e-05	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1.47e-05	8.68e-05	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1.47e-05	8.67e-05	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.47e-05	8.67e-05	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.47e-05	8.66e-05	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.46e-05	8.66e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	1.44e-05	8.54e-05	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.43e-05	8.45e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.42e-05	8.42e-05	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.4e-05	8.3e-05	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1.39e-05	8.19e-05	CbGpPWpGaD
Imipramine—SLC22A1—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.37e-05	8.13e-05	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.35e-05	7.96e-05	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1.33e-05	7.84e-05	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.32e-05	7.8e-05	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	1.32e-05	7.8e-05	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	1.32e-05	7.79e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.31e-05	7.76e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.29e-05	7.63e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.29e-05	7.62e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.28e-05	7.59e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.28e-05	7.57e-05	CbGpPWpGaD
Imipramine—CHRM3—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.27e-05	7.51e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.27e-05	7.5e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.26e-05	7.47e-05	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1.25e-05	7.38e-05	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	1.24e-05	7.36e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.24e-05	7.34e-05	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—APOE—amyotrophic lateral sclerosis	1.2e-05	7.12e-05	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	1.19e-05	7.04e-05	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—APOE—amyotrophic lateral sclerosis	1.18e-05	6.95e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.15e-05	6.8e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.14e-05	6.77e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.14e-05	6.74e-05	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	1.12e-05	6.62e-05	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—APOE—amyotrophic lateral sclerosis	1.11e-05	6.55e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.1e-05	6.48e-05	CbGpPWpGaD
Imipramine—CYP2B6—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.09e-05	6.46e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1.09e-05	6.43e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1.08e-05	6.39e-05	CbGpPWpGaD
Imipramine—CYP2E1—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.07e-05	6.32e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1.04e-05	6.12e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.01e-05	5.97e-05	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—TP53—amyotrophic lateral sclerosis	9.96e-06	5.89e-05	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—TP53—amyotrophic lateral sclerosis	9.95e-06	5.89e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	9.94e-06	5.88e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	9.92e-06	5.86e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	9.89e-06	5.84e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	9.85e-06	5.83e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	9.76e-06	5.77e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	9.76e-06	5.77e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	9.73e-06	5.75e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	9.71e-06	5.74e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—GSTP1—amyotrophic lateral sclerosis	9.58e-06	5.66e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	9.55e-06	5.64e-05	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—TP53—amyotrophic lateral sclerosis	9.4e-06	5.56e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	9.39e-06	5.55e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—APOE—amyotrophic lateral sclerosis	9.38e-06	5.55e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	9.37e-06	5.54e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	9.34e-06	5.52e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	9.31e-06	5.51e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	9.3e-06	5.5e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	9.22e-06	5.45e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	9.2e-06	5.44e-05	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—TP53—amyotrophic lateral sclerosis	9e-06	5.32e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	8.8e-06	5.2e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	8.57e-06	5.07e-05	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—TP53—amyotrophic lateral sclerosis	8.46e-06	5e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	8.43e-06	4.99e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	8.42e-06	4.98e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	8.39e-06	4.96e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	8.36e-06	4.94e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	8.28e-06	4.9e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	8.26e-06	4.88e-05	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—PTGS2—amyotrophic lateral sclerosis	8.25e-06	4.88e-05	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—PTGS2—amyotrophic lateral sclerosis	8.06e-06	4.76e-05	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—PTGS2—amyotrophic lateral sclerosis	7.59e-06	4.49e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—TP53—amyotrophic lateral sclerosis	7.38e-06	4.36e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—TP53—amyotrophic lateral sclerosis	7.34e-06	4.34e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—APOE—amyotrophic lateral sclerosis	7.24e-06	4.28e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—TP53—amyotrophic lateral sclerosis	7.02e-06	4.15e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—TP53—amyotrophic lateral sclerosis	6.48e-06	3.83e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—PTGS2—amyotrophic lateral sclerosis	6.43e-06	3.8e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—TP53—amyotrophic lateral sclerosis	6.37e-06	3.77e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	6.36e-06	3.76e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	6.34e-06	3.75e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—TP53—amyotrophic lateral sclerosis	6.32e-06	3.74e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—TP53—amyotrophic lateral sclerosis	6.26e-06	3.7e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—TP53—amyotrophic lateral sclerosis	6.24e-06	3.69e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—PTGS2—amyotrophic lateral sclerosis	4.96e-06	2.93e-05	CbGpPWpGaD
